TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,975,706 | -5.4% | 332,853 | +62.5% | 0.02% | +4.8% |
| Q2 2023 | $3,145,459 | +271.2% | 204,782 | +443.5% | 0.02% | +320.0% |
| Q1 2023 | $847,333 | +10491.7% | 37,676 | +10948.7% | 0.01% | – |
| Q3 2022 | $8,000 | -98.1% | 341 | -98.0% | 0.00% | -100.0% |
| Q2 2022 | $421,000 | -76.0% | 17,388 | -74.5% | 0.00% | -80.0% |
| Q1 2022 | $1,755,000 | -22.1% | 68,117 | -6.1% | 0.02% | -28.6% |
| Q4 2021 | $2,252,000 | +126.8% | 72,548 | +77.2% | 0.02% | +61.5% |
| Q3 2021 | $993,000 | -38.4% | 40,932 | -63.0% | 0.01% | -27.8% |
| Q2 2021 | $1,613,000 | +224.5% | 110,575 | +456.0% | 0.02% | +200.0% |
| Q1 2021 | $497,000 | -53.4% | 19,889 | -49.2% | 0.01% | -60.0% |
| Q4 2020 | $1,067,000 | – | 39,161 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |